Gilead Sciences (GILD) Given a $94.00 Price Target by Maxim Group Analysts
A number of other equities analysts also recently commented on GILD. Mizuho restated a buy rating on shares of Gilead Sciences in a report on Friday, September 29th. Berenberg Bank restated a buy rating and set a $86.00 target price (up previously from $79.00) on shares of Gilead Sciences in a report on Sunday, August 20th. Credit Suisse Group restated a buy rating and set a $82.00 target price on shares of Gilead Sciences in a report on Thursday, December 7th. Cowen restated an outperform rating and set a $90.00 target price on shares of Gilead Sciences in a report on Thursday, August 31st. Finally, Leerink Swann restated a market perform rating and set a $87.00 target price (up previously from $82.00) on shares of Gilead Sciences in a report on Wednesday, September 20th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and an average target price of $85.11.
Gilead Sciences (GILD) opened at $74.34 on Monday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The company has a market capitalization of $100,034.09, a P/E ratio of 7.99, a P/E/G ratio of -1.28 and a beta of 1.13. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.75 earnings per share. research analysts expect that Gilead Sciences will post 8.53 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.80%. Gilead Sciences’s payout ratio is presently 23.69%.
In other news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold 494,999 shares of company stock valued at $37,404,139 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.
Several large investors have recently modified their holdings of GILD. Welch Investments LLC purchased a new position in Gilead Sciences in the third quarter worth about $108,000. Penserra Capital Management LLC boosted its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. Wealthcare Advisory Partners LLC purchased a new position in Gilead Sciences in the third quarter worth about $133,000. American Beacon Advisors Inc. purchased a new position in Gilead Sciences in the first quarter worth about $143,000. Finally, Horan Capital Advisors LLC. purchased a new position in Gilead Sciences in the third quarter worth about $144,000. Hedge funds and other institutional investors own 76.23% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.